About MoviPrep

MoviPrep: a low-volume colonoscopy prep

The importance of a clean colon

Colonoscopy is a potentially lifesaving procedure, but it requires an effective preparation to thoroughly cleanse your colon and rectum. That's because your doctor needs a clear view to detect and remove abnormal growths that may otherwise grow into cancer. Without an effective colonoscopy prep, your doctor may not spot potentially cancerous growths (colon polyps).

MoviPrep—the #1-prescribed branded colonoscopy prep in the United States1

MoviPrep is a low-volume polyethylene glycol (PEG) osmotic colonoscopy preparation that is proven to effectively cleanse your colon.2 It was designed to provide you with a tolerable colonoscopy prep experience. MoviPrep is just as effective as 4-liter PEGs, but MoviPrep only requires you to drink 2 liters of PEG and 1 additional liter of the clear liquid of your choice. Plus, in clinical trials, it was shown that people may experience fewer gastrointestinal side effects with MoviPrep than with 4-liter colonoscopy preparations.

Table 1: The Most Common Drug-Related Adverse Reactions1 (≥ 2%) in the Study of MoviPrep vs. 4 Liter Polyethylene Glycol plus Electrolytes Solution

  MoviPrep©
(split dose)
N=180		 4L PEG + E2
N=179
  n (% = n/N) n (% = n/N)
Malaise 35 (19.4) 32 (17.9)
Nausea 26 (14.4) 36 (20.1)
Abdominal pain 24 (13.3) 27 (15.1)
Vomiting 14 (7.8) 23 (12.8)
Upper abdominal pain 10 (5.6) 11 (6.1)
Dyspepsia 5 (2.8) 2 (1.1)

1 Drug-related adverse reactions were advers events that were possibly, probably, or definitely related to the study drug.
2 4L PEG + E is 4 liter Polyethylene Glycol plus Electrolytes Solution.

MoviPrep is the #1-prescribed branded colonoscopy prep in the United States.1

Nine out of 10 patients would take MoviPrep again for their next procedure.3

Talk to your doctor about using MoviPrep for your colonoscopy preparation

If you are interested in a tolerable colonoscopy prep with less volume than traditional 4-liter bowel preps, talk to your doctor about MoviPrep.

Important Safety Information about MOVIPREP

MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP is contraindicated in patients with gastrointestinal (GI) obstruction, bowel perforation, gastric retention, ileus, toxic colitis or toxic megacolon, and patients who have had a severe hypersensitivity reaction to any of its components. MOVIPREP should be used with caution in patients at risk of or with fluid and electrolyte abnormalities, hyponatremia, arrhythmias, seizures, in patients with impaired renal function or patients taking concomitant medications that affect renal function, patients with known or suspected inflammatory bowel disease, patients with suspected GI obstruction or perforation, patients at risk for aspiration, and patients with glucose-6-phosphate dehydrogenase deficiency. Most common adverse reactions for split dosing (incidence ≥5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain. The most common adverse reactions for evening only dosing (incidence ≥5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness. MOVIPREP contains 233 mg of phenylalanine per treatment. Advise patients to hydrate adequately before, during, and after the use of MOVIPREP.

You are encouraged to report negative side effects to the FDA. Visit www.fda.gov/safety/medwatch/ or call 1-800-FDA-1088.

Complete Prescribing Information pdf icon

For Dummies is a registered trademark of Wiley Publishing, Inc.

References: 1. Medi-Span® Price Rx® [database online]. Indianapolis, IN: Wolters Kluwer Health. http://www.medispan.com/drug-pricing-analysis-pricerx.aspx. Accessed July 18, 2011. 2. MoviPrep [prescribing information]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2011. 3. Data on file, Salix Pharmaceuticals, Inc.